Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 87 | 3,955 | 14% |
| 2020 | 73 | 3,187 | 15% |
| 2021 | 81 | 3,383 | 19% |
| 2022 | 80 | 3,416 | 22% |
| 2023 | 91 | 3,802 | 25% |
| 2024 | 91 | 3,844 | 28% |
| 2025 from claims | – | 3,791 3,479–4,011 | 29% |
| 2026 forecast | – | 3,922 3,450–4,525 | 29% |
| 2027 forecast | – | 3,992 3,413–4,757 | 29% |
| 2028 forecast | – | 4,063 3,390–4,975 | 30% |
| 2029 forecast | – | 4,135 3,377–5,186 | 31% |
| 2030 forecast | – | 4,208 3,371–5,393 | 31% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 38% of the cases CMS names in Maryland; 52 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 29% hospital outpatient, 68% surgery center. The share outside the hospital has moved +10 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 10,751−1.7%/yr | −1.7%/yr | 4.9 | 18% | 11,800 in 2030+1.5%/yr |
| Texas | 182 | 9,000−1.4%/yr | −1.4%/yr | 4.2 | 17% | 11,000 in 2030+3.4%/yr |
| North Carolina | 103 | 4,811−5%/yr | −5%/yr | 4.9 | 5% | 5,000 in 2030+0.6%/yr |
| Virginia | 111 | 4,758−1.7%/yr | −1.7%/yr | 4.6 | 25% | 4,870 in 2030+0.4%/yr |
| Georgia | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.5 | 17% | 5,540 in 2030+2.7%/yr |
| Tennessee | 110 | 4,594−3.3%/yr | −3.3%/yr | 6.6 | 25% | 4,840 in 2030+0.9%/yr |
| South Carolina | 83 | 4,214−0.8%/yr | −0.8%/yr | 6.2 | 7% | 4,820 in 2030+2.3%/yr |
| Oklahoma | 58 | 2,956−0.1%/yr | −0.1%/yr | 6.1 | 1% | 3,150 in 2030+1.1%/yr |
| Mississippi | 43 | 2,629−1.4%/yr | −1.4%/yr | 7.1 | 30% | 2,760 in 2030+0.8%/yr |
| Alabama | 53 | 2,415−5.4%/yr | −5.4%/yr | 5.6 | 8% | 2,290 in 2030−0.9%/yr |
| Louisiana | 45 | 2,342−1%/yr | −1%/yr | 5.8 | 0% | 2,550 in 2030+1.4%/yr |
| Kentucky | 59 | 2,308−6.2%/yr | −6.2%/yr | 5.1 | 3% | 2,480 in 2030+1.2%/yr |
| Arkansas | 37 | 1,786−2.9%/yr | −2.9%/yr | 4.8 | 10% | 1,850 in 2030+0.6%/yr |
| West Virginia | 21 | 920−7.2%/yr | −7.2%/yr | 4.5 | 0% | 990 in 2030+1.3%/yr |
| Delaware | 19 | 805−2.9%/yr | −2.9%/yr | 4.7 | 31% | 860 in 2030+1.1%/yr |
| District of Columbia | 9 | 387+3.4%/yr | +3.4%/yr | 6.2 | 32% | 420 in 2030+1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 65 | 4,904−8.2%/yr | −8.2%/yr | 5.51.1× | 82% | 4,770 in 2030−0.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 37 | 2,575−1.2%/yr | −1.2%/yr | 3.11.2× | 16% | 2,650 in 2030+0.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 35 | 1,684+0.8%/yr | +0.8%/yr | 1.90.7× | 34% | 1,910 in 2030+2.1%/yr |
| Prostatectomy & nephrectomy | 15 | 867−3.9%/yr | −3.9%/yr | 1.00.8× | 0% | 990 in 2030+2.2%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
Calyxo leads with 90% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 3 companies reported engagement with Maryland’s surgeons worth $45K in consulting, speaking, meals and travel tied to these products, about $491 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.